Medical Crossfire®: Navigating Treatment Decisions in Advanced Prostate Cancer As New Options Emerge

Release Date: December 21, 2020
Expiration Date: December 21, 2021

Activity Overview

Prostate cancer is the leading type of cancer among men. It is estimated that in 2020 over 191,930 new cases of prostate cancer will be diagnosed, and nearly 33,330 men will die from the disease. The past decade has witnessed significant advances in the treatment of advanced/metastatic prostate cancer, particularly for patients with castration-resistant prostate cancer (CRPC), largely due to our growing insight into the biology of disease. The new treatments allow physicians to target previously unattainable therapeutic goals and treat patients who would have received suboptimal therapy because of lack of better treatment strategies. These agents have advanced patient care through new combinations, improved survival rates and personalized therapies, as well as allowed treatment of difficult-to-treat patients who have failed previous therapies.

The Medical Crossfire^®, one of PER^®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of metastatic and non-metastatic CRPC across lines of care. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with prostate cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astellas, Exelixis, Sanofi Genzyme, Clovis Oncology Inc.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, urologists, and other health care professionals interested in the treatment of prostate cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the rationale underlying the development of evolving therapeutic strategies for patients with CRPC
• Assess new and practice-changing data from landmark trials evaluating current and emerging approaches for patients with CRPC
• Utilize proactive strategies to monitor for and mitigate the impact of treatment-related toxicities among patients with CRPC
• Apply key evidence from trials that evaluated CRPC treatment strategies in the context of real-world case and sequencing scenarios encountered in clinical practice

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Chair

Philip Kantoff, MD
Chairman of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical School

Disclosures: Consultant: Bavarian Nordic Immunotherapeutics, GE Healthcare, DRGT, Janssen, OncoCellMDX, Progenity, Seer Biosciences, SynDevRx, Tarveda Therapeutics (previously Blend). Stock/ Shareholder: Cogent Biosciences, Context Therapeutics LLC, DRGT, Mirati, Placon, Seer Biosciences, Xlink.

Spouse receives Grant/Research Support from: Astellas, Janssen, Astra Zeneca, Bayer, and Merck and Consulting Fees from Bayer.

Faculty

Elisabeth I Heath, MD, FACP
Associate Center Director, Translational Sciences
Chair, Genitourinary Oncology Multidisciplinary Team
Director, Prostate Cancer Research
Karmanos Cancer Institute
Professor of Oncology and Medicine
Wayne State University School of Medicine
Detroit, MI

Disclosures: Grant/Research Support: Agensys, Astellas Pharma, AstraZeneca, Boehringer lngelheim, Bristol-Myers Squibb, Caris Life Sciences, Celgene, Celldex, Corcept Therapeutics, Curemeta, Dendreon eFFECTOR Therapeutics, Esanik, Fortis, Genentech/Roche, GlaxoSmithKline, lgnyta, lnovio Pharmaceuticals, Medivation , Merch Sharp & Dohme Merck, Millenium ,Oncolys BioPharma, Plexxicon, Synta, Seattle Genetics, Tokai Pharmaceuticals, Zenith Epigenetics. Consultant: Agensys. Speaker's Bureau: Sanofi.

Adam Stuart Kibel, MD
Chief, Division of Urology
Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center
Elliott Carr Cutler Professor of Surgery in Urology
Harvard Medical School
Boston, MA

Disclosures: Consultant: Janssen, Merck, BMS, Bayer.

William K. Oh, MD
Professor of Medicine and Urology
Chief of the Division of Hematology and Medical Oncology
Deputy Director of The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Consultant: Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Conjupro, Curio, Foundry, Janssen, Merck, Sanofi, Sema4, TeneoBio.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.